Alex Thurman Sells 2,511 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) CFO Alex Thurman sold 2,511 shares of the firm’s stock in a transaction that occurred on Wednesday, March 25th. The stock was sold at an average price of $106.46, for a total transaction of $267,321.06. Following the transaction, the chief financial officer owned 41,967 shares of the company’s stock, valued at approximately $4,467,806.82. The trade was a 5.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Glaukos Stock Down 0.0%

Shares of NYSE GKOS opened at $103.13 on Monday. The company’s 50 day moving average price is $112.94 and its 200-day moving average price is $102.07. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.06 and a current ratio of 4.69. Glaukos Corporation has a 52-week low of $73.16 and a 52-week high of $130.23. The company has a market capitalization of $5.99 billion, a P/E ratio of -31.63 and a beta of 0.70.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.06). Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The firm had revenue of $143.12 million for the quarter, compared to analyst estimates of $132.16 million. During the same quarter last year, the company earned ($0.40) earnings per share. The company’s quarterly revenue was up 35.6% compared to the same quarter last year. Equities analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Wells Fargo & Company lifted their price objective on Glaukos from $122.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. UBS Group upped their target price on Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, December 23rd. Wall Street Zen cut Glaukos from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Piper Sandler reiterated an “overweight” rating and issued a $165.00 target price on shares of Glaukos in a report on Wednesday, January 14th. Finally, Stephens boosted their price target on Glaukos from $115.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, January 2nd. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $133.69.

Hedge Funds Weigh In On Glaukos

Institutional investors have recently made changes to their positions in the stock. Hsbc Holdings PLC acquired a new stake in shares of Glaukos in the 4th quarter valued at about $209,000. Fund Advisors of America Inc FL bought a new stake in Glaukos in the 4th quarter valued at about $219,000. Corient Private Wealth LLC raised its stake in Glaukos by 999.3% during the 4th quarter. Corient Private Wealth LLC now owns 30,978 shares of the medical instruments supplier’s stock worth $3,498,000 after buying an additional 28,160 shares during the period. Invesco Ltd. raised its stake in Glaukos by 28.5% during the 4th quarter. Invesco Ltd. now owns 780,267 shares of the medical instruments supplier’s stock worth $88,100,000 after buying an additional 172,825 shares during the period. Finally, Summit Global Investments boosted its holdings in Glaukos by 151.3% in the fourth quarter. Summit Global Investments now owns 7,052 shares of the medical instruments supplier’s stock worth $796,000 after acquiring an additional 4,246 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.